660425-16-1 Usage
Uses
Used in Pharmaceutical Research:
2-Bromo-3,5-difluoropyridine is used as a key intermediate in the synthesis of new drugs, contributing to the development of innovative pharmaceuticals with enhanced therapeutic properties.
Used in Agrochemical Research:
In the agrochemical industry, 2-Bromo-3,5-difluoropyridine is utilized as a precursor for the development of novel pesticides, aiming to improve crop protection and yield.
Used in Organic Synthesis:
2-Bromo-3,5-difluoropyridine is employed as a reagent in organic synthesis to introduce fluorine and bromine atoms into organic compounds, which can be valuable for various applications in chemical and pharmaceutical industries.
Overall, 2-Bromo-3,5-difluoropyridine is a valuable and versatile compound that plays a crucial role in the development of new materials and chemicals across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 660425-16-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,0,4,2 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 660425-16:
(8*6)+(7*6)+(6*0)+(5*4)+(4*2)+(3*5)+(2*1)+(1*6)=141
141 % 10 = 1
So 660425-16-1 is a valid CAS Registry Number.
InChI:InChI=1/C5H2BrF2N/c6-5-4(8)1-3(7)2-9-5/h1-2H
660425-16-1Relevant articles and documents
DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
-
Paragraph 0210, (2016/02/16)
Disclosed are chemical entities of formula (I) wherein X, Y, Z, R1, R3, R4, R5 and R6 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of formula I.
PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER
-
, (2008/12/08)
The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.